Nature Hot Topic

A prospect for amyloid-β-removal therapy

Aducanumab is a recombinant human monoclonal antibody that selectively targets the amyloid-β (Aβ) peptide aggregates thought to play a part in the neurodegenerative process in Alzheimer's disease. Several Alzheimer's disease drugs have failed in development in recent years - including other anti-amyloid antibodies - so there is intense interest in any new developments. A new study reports interim results from a clinical trial of monthly infusions of aducanumab in subjects with prodromal or mild Alzheimer's disease. Treatment with aducanumab reduced brain Aβ plaques, an action accompanied by a dose-dependent slowing of clinical decline. The trial data support further development of aducanumab as an Aβ-removing therapy.

Nature Volume 537 Issue 7618

Top Ten Highlights

Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.

More Hot Topics

PrivacyMark System